- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02287519
Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention (START-OC)
February 27, 2020 updated by: Sharon Bober, Ph.D, Dana-Farber Cancer Institute
This research study is evaluating an educational intervention for women who have experienced changes in sexual function after treatment for ovarian cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this research is to study the effectiveness of an educational intervention for women who have experienced changes in sexual function after treatment for ovarian cancer.
The aim is to develop an effective intervention to help women manage these changes and restore sexual health and functioning.
This study consists of attending a group educational session followed by a one-on-one telephone counseling session.
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women diagnosed with Stage1-IV ovarian cancer
- Prognosis of at least one year to live (as assessed by provider)
- Endorsement of at least one sexual symptom (see Appendix A for eligibility screening)
- English speaking
- Signed informed consent
Exclusion Criteria:
- History of pelvic radiation
- Cognitive impairment which would interfere with the ability to participate in the study (as assessed by provider)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Support Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in sexual dysfunction will be assessed by change on the Female Sexual Function Index (FSFI).
Time Frame: Baseline, 2 month Post Intervention, 6 Month Post Intervention
|
Baseline, 2 month Post Intervention, 6 Month Post Intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sexual self-efficacy will be assessed by change on the Sexual Self-Efficacy Scale
Time Frame: Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
|
|
Improvement in sexual knowledge will be assessed by change on the Sexual Knowledge after Ovarian Cancer questionnaire
Time Frame: Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
|
|
Change in psychological distress will be assessed by change on the BSI-18 (Brief Symptom Inventory)
Time Frame: Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
|
|
Feasibility of conducting a group sexual health intervention via webinar format will be assessed with descriptive data and qualitative feedback from participants
Time Frame: Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
To explore and describe women's experience of webinar platform.
|
Baseline, 2 Month Post Intervention, 6 Month Post Intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sharon Bober, Ph.D, Dana-Farber Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
February 1, 2018
Study Completion (Actual)
December 1, 2019
Study Registration Dates
First Submitted
November 4, 2014
First Submitted That Met QC Criteria
November 7, 2014
First Posted (Estimate)
November 10, 2014
Study Record Updates
Last Update Posted (Actual)
February 28, 2020
Last Update Submitted That Met QC Criteria
February 27, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- 14-368
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.